DC therapy for prostate cancer.
The wide range of currently available treatments for metastatic prostate cancer have demonstrated a modest palliative effect, but none to date has shown an increase in overall survival. The immune system has evolved to protect against infection, however, the modulation of this system represents the possibility of allowing it to identify and destroy cancer cells. The immune system is capable of inciting a powerful immune response against tissues, in the form of transplant rejection, and the potential exists to harness these powers to fight against tumors. Modest clinical responses have been seen in patients with metastatic prostate cancer treated with DC therapies; however, no increase in overall survival has been demonstrated. The current state of DC immunotherapy for prostate cancer is reviewed.
Swindle
P W
PW
Mater Prostate Cancer Research Centre, Mater Medical Research Institute, Queensland, South Brisbane, Australia.
Tepes
S
S
Clements
J
J
D000728:Androgens / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000276:immunology* / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002277:Carcinoma / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation*; D018572:Disease-Free Survival; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D008297:Male; D010455:Peptides / Q000276:immunology; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*
D000728:Androgens; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016207:Cytokines; D006680:HLA Antigens; D010455:Peptides